Approval for the contak cd, contak cd 2, renewal, and renewal 3 devices.  These devices are indicated for patients with moderate to severe heart failure (nyha iii/iv) who remain symptomatic despite stable, optimal heart failure drug therapy and have left ventricular dysfunction (ef <= 35%) and qrs duration >= 120 ms.